Amin Rostami-Hodjegan

List of Publications by Year in Descending Order

306 papers	14,663 citations	66 h-index	106 g-index
324 ext. papers	16,546 ext. citations	4.3 avg, IF	6.81 L-index

#	Paper	IF	Citations
306	In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.. *AAPS Journal*, **2022**, 24, 28	3.7	2
305	Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling.. *AAPS Journal*, **2022**, 24, 21	3.7	2
304	A family of QconCATs (Quantification conCATemers) for the quantification of human pharmacological target proteins.. *Journal of Proteomics*, **2022**, 104572	3.9	1
303	Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities.. *Clinical Pharmacology and Therapeutics*, **2022**,	6.1	2
302	.. *Drug Metabolism and Disposition*, **2022**,	4	2
301	APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC AND PHARMACODYNAMIC (PBPK/PD) MODELING COMPRISING TRANSPORTERS **2022**, 475-496		0
300	The Interplay Between Drug Release and Intestinal Gut-Wall Metabolism **2022**, 65-86		
299	Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease.. *Journal of Proteomics*, **2022**, 104601	3.9	0
298	Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects. *British Journal of Clinical Pharmacology*, **2021**,	3.8	2
297	Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 1190-1195	6.1	1
296	Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help. *Biopharmaceutics and Drug Disposition*, **2021**, 42, 118-127	1.7	5
295	Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions. *Clinical Pharmacokinetics*, **2021**, 60, 1187-1199	6.2	3
294	Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes. *Drug Metabolism and Disposition*, **2021**, 49, 610-618	4	4
293	Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 10, 420-427	4.5	5
292	Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. *Drug Metabolism and Disposition*, **2021**, 49, 563-571	4	2
291	Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 10, 467-477	4.5	4
290	Application of proteomic data in the translation of in vitro observations to associated clinical outcomes.. *Drug Discovery Today: Technologies*, **2021**, 39, 13-22	7.1	2

289	Label-Free Quantitative Proteomics and Substrate-Based Mass Spectrometry Imaging of Xenobiotic Metabolizing Enzymes in Ex Vivo Human Skin and a Human Living Skin Equivalent Model. *Drug Metabolism and Disposition*, **2021**, 49, 39-52	4	3
288	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. *Annual Review of Pharmacology and Toxicology*, **2021**, 61, 225-245	17.9	20
287	Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms. *Biopharmaceutics and Drug Disposition*, **2021**, 42, 107-117	1.7	15
286	Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1136-1146	6.1	8
285	Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 222-232	6.1	22
284	Does "Birth" as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine Bias. *Journal of Clinical Pharmacology*, **2021**, 61, 159-171	2.9	13
283	Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 388-401	6.1	4
282	Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment. *Molecular Pharmaceutics*, **2021**, 18, 3563-3577	5.6	2
281	Quantitative Proteomic Map of Enzymes and Transporters in the Human Kidney: Stepping Closer to Mechanistic Kidney Models to Define Local Kinetics. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 1389-1400	6.1	4
280	Application of the Nested Enzyme-Within-Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects. *CPT: Pharmacometrics and Systems Pharmacology*, **2020**, 9, 617-627	4.5	
279	Proteomic characterisation of drug metabolising enzymes and drug transporters in pig liver. *Xenobiotica*, **2020**, 50, 1208-1219	2	2
278	Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives. *Pharmaceutical Research*, **2020**, 37, 95	4.5	6
277	Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine-Drug Interactions. *CPT: Pharmacometrics and Systems Pharmacology*, **2020**, 9, 282-293	4.5	9
276	The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study. *AAPS Journal*, **2020**, 22, 87	3.7	11
275	A Novel Physiologically‐Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations. *CPT: Pharmacometrics and Systems Pharmacology*, **2020**, 9, 310-321	4.5	6
274	Mass Spectrometry of Human Transporters. *Annual Review of Analytical Chemistry*, **2020**, 13, 223-247	12.5	3
273	Virtual Twins: Understanding the Data Required for Model-Informed Precision Dosing. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 742-745	6.1	15
272	Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine. *Drug Metabolism and Disposition*, **2020**, 48, 245-254	4	41

271	Scaling Factors for Clearance in Adult Liver Cirrhosis. *Drug Metabolism and Disposition*, **2020**, 48, 1271-1282	4	8
270	Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 152, 236-247	5.7	12
269	IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 156, 50-63	5.7	10
268	Physiologically Based Pharmacokinetics as a Component of Model-Informed Drug Development: Where We Were, Where We Are, and Where We Are Heading. *Journal of Clinical Pharmacology*, **2020**, 60 Suppl 1, S12-S16	2.9	2
267	Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models. *AAPS Journal*, **2020**, 22, 93	3.7	14
266	Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. *FEBS Letters*, **2020**, 594, 4134-4150	3.8	12
265	Characterization of CYP2B6 K262R allelic variants by quantitative allele-specific proteomics using a QconCAT standard. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, 178, 112901	3.5	5
264	Quantitative Translation of Microfluidic Transporter Data to Reveals Impaired Albumin-Facilitated Indoxyl Sulfate Secretion in Chronic Kidney Disease. *Molecular Pharmaceutics*, **2019**, 16, 4551-4562	5.6	18
263	Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 118-126	4.5	11
262	Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 525-543	6.1	54
261	Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics. *Journal of Pharmacokinetics and Pharmacodynamics*, **2019**, 46, 137-154	2.7	13
260	Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method. *AAPS Journal*, **2019**, 21, 38	3.7	6
259	Drug-Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 1289-1291	6.1	0
258	Proteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients. *Molecular Pharmaceutics*, **2019**, 16, 1220-1233	5.6	47
257	Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice. *Pharmacology & Therapeutics*, **2019**, 203, 107397	13.9	13
256	A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. *AAPS Journal*, **2019**, 21, 81	3.7	4
255	Precision medicine technology hype or reality? The example of computer-guided dosing. *F1000Research*, **2019**, 8, 1709	3.6	1
254	The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall. *European Journal of Pharmaceutical Sciences*, **2019**, 131, 195-207	5.1	5

253	Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 368, 157-168	4.7	15
252	Quantification of Proteins Involved in Drug Metabolism and Disposition in the Human Liver Using Label-Free Global Proteomics. *Molecular Pharmaceutics*, **2019**, 16, 632-647	5.6	38
251	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. *AAPS Journal*, **2019**, 21, 17	3.7	14
250	Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development. *Clinical Pharmacology in Drug Development*, **2019**, 8, 418-425	2.3	16
249	Response to "Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method". *Journal of Proteome Research*, **2019**, 18, 574	5.6	2
248	Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice: Drug-Drug and Food-Drug Interactions. *Journal of Clinical Pharmacology*, **2018**, 58, 704-716	2.9	8
247	Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 175-185	4.5	18
246	Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels. *Journal of Neurochemistry*, **2018**, 146, 670-685	6	37
245	Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 1219-1228	6.1	21
244	Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide. *British Journal of Clinical Pharmacology*, **2018**, 84, 972-986	3.8	16
243	Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition. *Clinical Pharmacokinetics*, **2018**, 57, 1149-1171	6.2	24
242	Revisiting Principles Behind Drug Clearance and Organ Extraction. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 388-389	6.1	1
241	Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5'-Diphosphate-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity. *Drug Metabolism and Disposition*, **2018**, 46, 805-812	4	16
240	Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 224-232	6.1	46
239	Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz. *Frontiers in Pharmacology*, **2018**, 9, 247	5.6	2
238	Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products. *Journal of Pharmaceutical Sciences*, **2018**, 107, 2519-2530	3.9	11
237	Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials". *Clinical Pharmacokinetics*, **2018**, 57, 1471-1472	6.2	2
236	Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. *Pharmaceutical Research*, **2018**, 35, 182	4.5	15

235	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. *British Journal of Clinical Pharmacology*, **2018**, 84, 462-476	3.8	40
234	Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. *Expert Opinion on Drug Metabolism and Toxicology*, **2018**, 14, 1315-1330	5.5	7
233	GASP and FASP are Complementary for LC-MS/MS Proteomic Analysis of Drug-Metabolizing Enzymes and Transporters in Pig Liver. *Proteomics*, **2018**, 18, e1800200	4.8	9
232	Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory. *Pharmaceutical Research*, **2018**, 35, 209	4.5	5
231	Physiologically based pharmacokinetic modelling to guide drug delivery in older people. *Advanced Drug Delivery Reviews*, **2018**, 135, 85-96	18.5	29
230	First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 374-383	4.5	17
229	Comment on "In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Models". *Molecular Pharmaceutics*, **2017**, 14, 336-339	5.6	7
228	Quantifying gut wall metabolism: methodology matters. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 155-160	1.7	15
227	Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 187-208	1.7	13
226	Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 94-114	1.7	27
225	Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance. *Drug Metabolism and Disposition*, **2017**, 45, 556-568	4	24
224	Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. *Clinical Pharmacology and Therapeutics*, **2017**, 101, 646-656	6.1	105
223	Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes. *Drug Metabolism and Disposition*, **2017**, 45, 666-675	4	33
222	Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist. *Journal of Pharmaceutical Sciences*, **2017**, 106, 2188-2194	3.9	
221	The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model. *Journal of Pharmaceutical Sciences*, **2017**, 106, 2826-2838	3.9	11
220	Systems Toxicology: Real World Applications and Opportunities. *Chemical Research in Toxicology*, **2017**, 30, 870-882	4	64
219	The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 260-270	1.7	11
218	Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes. *Molecular Pharmaceutics*, **2017**, 14, 3142-3151	5.6	80

217	Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. *European Journal of Pharmaceutical Sciences*, **2017**, 109, 111-120	5.1	38
216	Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop. *Journal of Clinical Pharmacology*, **2017**, 57, 105-109	2.9	6
215	Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity. *Drug Metabolism and Disposition*, **2017**, 45, 1102-1112	4	32
214	IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 610-625	5.1	43
213	Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?. *Clinical Pharmacokinetics*, **2017**, 56, 273-285	6.2	61
212	IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 598-609	5.1	30
211	IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 626-642	5.1	34
210	Biopharmaceutics data management system for anonymised data sharing and curation: First application with orbito IMI project. *Computer Methods and Programs in Biomedicine*, **2017**, 140, 29-44	6.9	5
209	Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 360, 484-495	4.7	45
208	Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. *Translational Cancer Research*, **2017**, 6, S1512-S1529	0.3	17
207	Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. *Clinical Pharmacology and Therapeutics*, **2016**, 100, 75-87	6.1	41
206	Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process. *AAPS Journal*, **2016**, 18, 1144-1158	3.7	13
205	Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data. *Drug Metabolism and Pharmacokinetics*, **2016**, 31, 224-33	2.2	42
204	Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio. *Drug Metabolism and Disposition*, **2016**, 44, 1099-102	4	21
203	Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. *European Journal of Pharmaceutical Sciences*, **2016**, 88, 70-82	5.1	67
202	In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition. *Drug Metabolism and Disposition*, **2016**,	4	27
201	In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells. *Drug Metabolism and Disposition*, **2016**, 44, 297-307	4	34
200	Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. *AAPS Journal*, **2016**, 18, 589-604	3.7	39

199	Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions. *AAPS Journal*, **2016**, 18, 321-32	3.7	24
198	Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics. *Drug Metabolism and Disposition*, **2016**, 44, 992-8	4	21
197	Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. *AAPS Journal*, **2016**, 18, 1067-1081	3.7	33
196	Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. *European Journal of Pharmaceutical Sciences*, **2016**, 94, 59-71	5.1	37
195	Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2. *Journal of Pharmaceutical Sciences*, **2016**, 105, 1370-5	3.9	4
194	Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. *Drug Metabolism and Disposition*, **2016**, 44, 821-32	4	58
193	Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS Formulation of Oxybutynin. *AAPS Journal*, **2016**, 18, 1532-1549	3.7	19
192	Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6. *European Journal of Pharmaceutical Sciences*, **2016**, 92, 131-6	5.1	2
191	Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. *AAPS Journal*, **2016**, 18, 1082-1094	3.7	23
190	Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients. *CPT: Pharmacometrics and Systems Pharmacology*, **2016**, 5, 20-30	4.5	23
189	Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. *Pharmaceutical Research*, **2015**, 32, 1864-83	4.5	48
188	Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique. *Journal of Pharmaceutical and Biomedical Analysis*, **2015**, 110, 27-33	3.5	45
187	Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics for in vitro-in vivo extrapolation of drug metabolism and transport and considerations in selecting appropriate techniques. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 1357-69	5.5	21
186	Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations. *British Journal of Clinical Pharmacology*, **2015**, 80, 1021-30	3.8	20
185	Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue. *Drug Metabolism and Disposition*, **2015**, 43, 424-32	4	57
184	The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. *Pharmaceutical Research*, **2015**, 32, 3927-36	4.5	43
183	Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. *Journal of Pharmacokinetics and Pharmacodynamics*, **2015**, 42, 349-73	2.7	11
182	Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site. *AAPS Journal*, **2015**, 17, 1268-79	3.7	14

181	Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine. *Pharmaceutical Research*, **2015**, 32, 74-90	4.5	34
180	Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. *British Journal of Clinical Pharmacology*, **2015**, 79, 48-55	3.8	154
179	Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making. *CPT: Pharmacometrics and Systems Pharmacology*, **2015**, 4, 313-5	4.5	41
178	Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 245-57	1.7	87
177	Complex patients - complex DDI: is there a straight way forward?. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 69-70	1.7	2
176	A proposal for scientific framework enabling specific population drug dosing recommendations. *Journal of Clinical Pharmacology*, **2015**, 55, 1073-8	2.9	34
175	Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption. *AAPS Journal*, **2015**, 17, 1177-92	3.7	14
174	Ten years of QconCATs: Application of multiplexed quantification to small medically relevant proteomes. *International Journal of Mass Spectrometry*, **2015**, 391, 93-104	1.9	13
173	Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. *European Journal of Pharmaceutical Sciences*, **2015**, 67, 32-44	5.1	25
172	Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. *Clinical Pharmacokinetics*, **2015**, 54, 567-8	6.2	4
171	Choice of LC-MS methods for the absolute quantification of drug-metabolizing enzymes and transporters in human tissue: a comparative cost analysis. *AAPS Journal*, **2015**, 17, 438-46	3.7	32
170	The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. *Pharmaceutical Research*, **2014**, 31, 720-30	4.5	18
169	In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 99-151	5.1	196
168	Pharmacometrics in pregnancy: An unmet need. *Annual Review of Pharmacology and Toxicology*, **2014**, 54, 53-69	17.9	62
167	Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. *Drug Metabolism and Disposition*, **2014**, 42, 500-10	4	121
166	Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. *Drug Metabolism and Disposition*, **2014**, 42, 1349-56	4	136
165	A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. *Clinical Pharmacokinetics*, **2014**, 53, 625-36	6.2	80
164	Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 292-9	5.1	80

163	Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information. *CPT: Pharmacometrics and Systems Pharmacology*, **2014**, 3, e130	4.5	19
162	Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. *CPT: Pharmacometrics and Systems Pharmacology*, **2014**, 3, e124	4.5	56
161	Can We Rationalize Oral Drug Exposure Following Bariatric Surgery to Meet the Pharmacotherapeutic Needs of a Growing Patient Population? Commentary on: Lithium Toxicity Following Roux-en-Y Gastric Bypass *Bariatric Surgical Patient Care*, **2014**, 9, 81-83	0.4	
160	Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. *Frontiers in Immunology*, **2014**, 5, 670	8.4	19
159	Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. *Drug Metabolism and Disposition*, **2014**, 42, 2016-22	4	96
158	Lost in centrifugation: accounting for transporter protein losses in quantitative targeted absolute proteomics. *Drug Metabolism and Disposition*, **2014**, 42, 1766-72	4	30
157	Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. *Frontiers in Pharmacology*, **2014**, 5, 258	5.6	32
156	Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. *British Journal of Clinical Pharmacology*, **2014**, 77, 554-70	3.8	74
155	Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. *Drug Metabolism and Disposition*, **2014**, 42, 1478-84	4	71
154	Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?. *Journal of Clinical Pharmacology*, **2014**, 54, 311-7	2.9	3
153	Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. *Biopharmaceutics and Drug Disposition*, **2014**, 35, 353-61	1.7	35
152	Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. *Clinical Pharmacology and Therapeutics*, **2014**, 96, 90-100	6.1	41
151	PBPK models for the prediction of in vivo performance of oral dosage forms. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 300-21	5.1	210
150	Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 240-9	5.1	34
149	Animal versus human oral drug bioavailability: do they correlate?. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 280-91	5.1	121
148	A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. *Clinical Pharmacokinetics*, **2014**, 53, 73-87	6.2	121
147	Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. *AAPS Journal*, **2014**, 16, 568-76	3.7	55
146	The modulating effects of endogenous substances on drug metabolising enzymes and implications for inter-individual variability and quantitative prediction. *Current Drug Metabolism*, **2014**, 15, 599-619	3.5	6

145	Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. *European Journal of Clinical Pharmacology*, **2013**, 69, 1311-20	2.8	17
144	The simcyp population based simulator: architecture, implementation, and quality assurance. *In Silico Pharmacology*, **2013**, 1, 9	4.3	66
143	Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. *Journal of Proteome Research*, **2013**, 12, 5934-42	5.6	47
142	Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. *Biopharmaceutics and Drug Disposition*, **2013**, 34, 2-28	1.7	84
141	Do children have the same vulnerability to metabolic drug□drug interactions as adults? A critical analysis of the literature. *Journal of Clinical Pharmacology*, **2013**, 53, 559-66	2.9	29
140	Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. *Expert Review of Clinical Pharmacology*, **2013**, 6, 143-57	3.8	41
139	A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. *Clinical Pharmacology and Therapeutics*, **2013**, 94, 260-8	6.1	62
138	Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. *Journal of Clinical Pharmacology*, **2013**, 53, 857-65	2.9	47
137	Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. *Journal of Pharmaceutical Sciences* , **2013**, 102, 3145-60	3.9	47
136	Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. *Journal of Pharmaceutical Sciences*, **2013**, 102, 3161-73	3.9	45
135	A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. *Drug Metabolism and Disposition*, **2013**, 41, 801-13	4	72
134	Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine. *CPT: Pharmacometrics and Systems Pharmacology*, **2013**, 2, e47	4.5	16
133	Pharmacometrics and Systems Pharmacology Software Tutorials and Use: Comments and Guidelines for PSP Contributions. *CPT: Pharmacometrics and Systems Pharmacology*, **2013**, 2, e86	4.5	2
132	Response to "The link between pharmacodynamics and physiologically based pharmacokinetic models". *Clinical Pharmacology and Therapeutics*, **2013**, 93, 152	6.1	8
131	Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM). *AAPS Advances in the Pharmaceutical Sciences Series*, **2013**, 155-177	0.5	39
130	A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. *Journal of Pharmacy and Pharmacology*, **2012**, 64, 1008-24	4.8	41
129	Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. *British Journal of Clinical Pharmacology*, **2012**, 74, 774-87	3.8	34
128	A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. *British Journal of Clinical Pharmacology*, **2012**, 74, 873-85	3.8	80

127	Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. *Clinical Pharmacology and Therapeutics*, **2012**, 92, 50-61	6.1	235
126	Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. *Clinical Pharmacokinetics*, **2012**, 51, 365-96	6.2	210
125	Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. *Journal of Pharmaceutical Sciences*, **2012**, 101, 2584-95	3.9	42
124	Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. *Journal of Clinical Psychopharmacology*, **2012**, 32, 666-71	1.7	10
123	From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties. *CPT: Pharmacometrics and Systems Pharmacology*, **2012**, 1, e10	4.5	29
122	Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. *Current Drug Metabolism*, **2012**, 13, 778-86	3.5	29
121	Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. *Current Drug Metabolism*, **2012**, 13, 695-720	3.5	35
120	A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. *CPT: Pharmacometrics and Systems Pharmacology*, **2012** , 1, e3	4.5	61
119	Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. *Clinical Pharmacokinetics*, **2011**, 50, 809-22	6.2	52
118	Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. *Xenobiotica*, **2011**, 41, 623-38	2	45
117	Modeling and predicting drug pharmacokinetics in patients with renal impairment. *Expert Review of Clinical Pharmacology*, **2011**, 4, 261-74	3.8	110
116	Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. *Paediatric Anaesthesia*, **2011**, 21, 291-301	1.8	123
115	Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. *British Journal of Clinical Pharmacology*, **2011**, 71, 72-87	3.8	58
114	Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. *European Journal of Pharmaceutical Sciences*, **2011**, 43, 160-73	5.1	73
113	Physiologically-Based Pharmacokinetics **2011**, 361-386		
112	Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. *Biopharmaceutics and Drug Disposition*, **2011**, 32, 303-18	1.7	30
111	Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. *Biopharmaceutics and Drug Disposition*, **2011**, 32, 498-506	1.7	7
110	The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. *Drug Metabolism and Disposition*, **2011**, 39, 2020-33	4	74

109	Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. *Drug Metabolism and Disposition*, **2011**, 39, 170-3	4	85
108	Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry [corrected]. *Drug Metabolism and Disposition*, **2011**, 39, 2130-4	4	68
107	Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. *Current Drug Metabolism*, **2010**, 11, 716-29	3.5	145
106	A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. *Clinical Pharmacokinetics*, **2010**, 49, 189-206	6.2	138
105	Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor expression in human lung. *Pulmonary Pharmacology and Therapeutics*, **2010**, 23, 71-7	3.5	1
104	Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. *Current Drug Metabolism*, **2010**, 11, 678-85	3.5	50
103	Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. *European Journal of Pharmaceutical Sciences*, **2010**, 39, 298-309	5.1	144
102	Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. *Biopharmaceutics and Drug Disposition*, **2010**, 31, 516-32	1.7	31
101	Translation of In Vitro Metabolic Data to Predict In Vivo Drug-Drug Interactions: IVIVE and Modeling and Simulations **2010**, 317-341		2
100	Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. *Journal of Clinical Pharmacology*, **2009**, 49, 147-54	2.9	26
99	A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 53-75	2.2	258
98	Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. *Xenobiotica*, **2009**, 39, 227-35	2	36
97	Modified-release hydrocortisone to provide circadian cortisol profiles. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1548-54	5.6	220
96	Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism. *Journal of Pharmaceutical Sciences*, **2009**, 98, 763-71	3.9	12
95	Assessment of inter-individual variability in predicted phenytoin clearance. *European Journal of Clinical Pharmacology*, **2009**, 65, 1203-10	2.8	13
94	Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. *Pharmaceutical Statistics*, **2009**, 8, 186-202	1	11
93	Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. *British Journal of Clinical Pharmacology*, **2009**, 67, 29-37	3.8	45
92	Population-based mechanistic prediction of oral drug absorption. *AAPS Journal*, **2009**, 11, 225-37	3.7	298

91	The Simcyp population-based ADME simulator. *Expert Opinion on Drug Metabolism and Toxicology*, **2009**, 5, 211-23	5.5	375
90	Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate. *Fertility and Sterility*, **2009**, 91, 1135-40	4.8	10
89	Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. *Current Drug Metabolism*, **2009**, 10, 420-32	3.5	63
88	Development of CYP2D6 and CYP3A4 in the first year of life. *Clinical Pharmacology and Therapeutics*, **2008**, 83, 670-1	6.1	64
87	Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. *Clinical Endocrinology*, **2008**, 68, 130-5	3.4	67
86	Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. *Drug Metabolism and Disposition*, **2008**, 36, 2405-9	4	94
85	CYP2D6 is primarily responsible for the metabolism of clomiphene. *Drug Metabolism and Pharmacokinetics*, **2008**, 23, 101-5	2.2	15
84	Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. *Current Drug Metabolism*, **2008**, 9, 384-94	3.5	189
83	The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. *Journal of Clinical Psychopharmacology*, **2008**, 28, 523-9	1.7	42
82	Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. *Xenobiotica*, **2007**, 37, 1225-56	2	67
81	Determination by liquid chromatography-mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2007**, 847, 296-9	3.2	17
80	Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. *Nature Reviews Drug Discovery*, **2007**, 6, 140-8	64.1	414
79	Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor-mediated responses in human lung mast cells. *British Journal of Pharmacology*, **2007**, 152, 323-31	8.6	14
78	Response from authors. *Journal of Clinical Pharmacy and Therapeutics*, **2007**, 32, 325-326	2.2	
77	The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. *British Journal of Clinical Pharmacology*, **2007**, 64, 14-26	3.8	39
76	Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA). *European Journal of Pharmaceutical Sciences*, **2007**, 31, 53-61	5.1	15
75	Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. *European Journal of Pharmaceutical Sciences*, **2007**, 31, 232-41	5.1	27
74	Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. *European Journal of Pharmaceutical Sciences*, **2007**, 32, 8-16	5.1	12

73	Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. *Current Drug Metabolism*, **2007**, 8, 33-45	3.5	349
72	Prediction of intestinal first-pass drug metabolism. *Current Drug Metabolism*, **2007**, 8, 676-84	3.5	286
71	Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. *Drug Metabolism and Disposition*, **2007**, 35, 1733-6	4	15
70	Misuse of the well-stirred model of hepatic drug clearance. *Drug Metabolism and Disposition*, **2007**, 35, 501-2	4	118
69	Evaluation of an existing nomogram for predicting the response to clomiphene citrate. *Fertility and Sterility*, **2007**, 87, 597-602	4.8	20
68	Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. *Journal of Clinical Pharmacology*, **2007**, 47, 175-86	2.9	32
67	Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. *Journal of Pharmaceutical Sciences*, **2006**, 95, 2778-87	3.9	28
66	A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. *Current Drug Metabolism*, **2006**, 7, 315-34	3.5	122
65	The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). *Journal of Psychopharmacology*, **2006**, 20, 834-41	4.6	25
64	Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. *Xenobiotica*, **2006**, 36, 499-513	2	67
63	Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. *Clinical Pharmacokinetics*, **2006**, 45, 931-56	6.2	363
62	Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. *Xenobiotica*, **2006**, 36, 473-97	2	179
61	Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. *Xenobiotica*, **2006**, 36, 567-80	2	77
60	Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. *Journal of Psychopharmacology*, **2006**, 20, 842-9	4.6	74
59	Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. *Clinical Endocrinology*, **2006**, 65, 45-50	3.4	73
58	A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. *Journal of Clinical Pharmacy and Therapeutics*, **2006**, 31, 477-84	2.2	9
57	Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?. *Journal of Assisted Reproduction and Genetics*, **2006**, 23, 427-31	3.4	
56	Can saliva replace plasma for the monitoring of methadone?. *Therapeutic Drug Monitoring*, **2005**, 27, 580-6	3.2	21

55	Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. *European Journal of Pharmaceutical Sciences*, **2005**, 26, 334-40	5.1	53
54	Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. *International Journal of Cancer*, **2005**, 113, 364-71	7.5	138
53	Changes in liver volume from birth to adulthood: a meta-analysis. *Liver Transplantation*, **2005**, 11, 1481-93	4.5	231
52	Changes to methadone clearance during pregnancy. *European Journal of Clinical Pharmacology*, **2005**, 61, 763-8	2.8	69
51	Toxicokinetics and metabolism. *ATLA Alternatives To Laboratory Animals*, **2005**, 33 Suppl 1, 147-75	2.1	13
50	Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs. *Journal of Psychopharmacology*, **2005**, 19, 67-70	4.6	14
49	Timing and type of glucocorticoid replacement in adult congenital adrenal hyperplasia. *Hormone Research in Paediatrics*, **2005**, 64 Suppl 2, 67-70	3.3	12
48	Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. *Drug Metabolism and Disposition*, **2004**, 32, 1213-7	4	85
47	Predicting the clearance of CYP2C9 substrates. *Drug Metabolism and Disposition*, **2004**, 32, 1522; author reply 1523	4	8
46	Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. *Xenobiotica*, **2004**, 34, 151-78	2	183
45	Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. *Clinical Endocrinology*, **2004**, 61, 367-75	3.4	173
44	Cytochrome P450 3A expression and activity in the human small intestine. *Clinical Pharmacology and Therapeutics*, **2004**, 76, 391	6.1	67
43	'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. *Drug Discovery Today: Technologies*, **2004**, 1, 441-8	7.1	173
42	Monitoring plasma concentrations to individualize treatment with clomiphene citrate. *Fertility and Sterility*, **2004**, 81, 1187-93	4.8	43
41	Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. *Journal of Clinical Psychopharmacology*, **2004**, 24, 70-8	1.7	170
40	Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. *Journal of Clinical Pharmacology*, **2004**, 44, 1398-404	2.9	22
39	Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. *Pharmaceutical Research*, **2003**, 20, 1668-73	4.5	69
38	The effects of dose staggering on metabolic drug-drug interactions. *European Journal of Pharmaceutical Sciences*, **2003**, 20, 223-32	5.1	36

37	A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. *British Journal of Clinical Pharmacology*, **2003**, 56, 220-4	3.8	31
36	Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. *British Journal of Clinical Pharmacology*, **2003**, 56, 57-67	3.8	28
35	Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. *British Journal of Clinical Pharmacology*, **2003**, 56, 433-40	3.8	128
34	Determination of midazolam and 1'-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2003**, 783, 303-7	3.2	24
33	Influence of the thr164ile polymorphism in the beta2-adrenoceptor on the effects of beta-adrenoceptor agonists on human lung mast cells. *International Immunopharmacology*, **2003**, 3, 91-5	5.8	15
32	An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. *British Journal of Clinical Pharmacology*, **2002**, 54, 140-6	3.8	24
31	A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. *Drug Development and Industrial Pharmacy*, **2002**, 28, 533-43	3.6	29
30	Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. *British Journal of Anaesthesia*, **2002**, 89, 428-437	5.4	37
29	Analysis of solvent central nervous system toxicity and ethanol interactions using a human population physiologically based kinetic and dynamic model. *Regulatory Toxicology and Pharmacology*, **2002**, 35, 165-76	3.4	15
28	A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. I. A four-way crossover study to compare the concentration-time profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers. *Drug Development and Industrial Pharmacy*, **2002**, 28, 523-31	3.6	38
27	The effects of portal shunts on intestinal cytochrome P450 3A activity. *Hepatology*, **2002**, 35, 1549-50; author reply 1550-1	11.2	33
26	Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. *British Journal of Anaesthesia*, **2002**, 89, 428-37	5.4	13
25	Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. *British Journal of Clinical Pharmacology*, **2001**, 52, 35-43	3.8	30
24	The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. *British Journal of Cancer*, **2001**, 84, 1126-34	8.7	262
23	Journal impact factors: a 'bioequivalence' issue?. *British Journal of Clinical Pharmacology*, **2001**, 51, 111-7	3.8	12
22	The placebo response to citric acid-induced cough: pharmacodynamics and gender differences. *Pulmonary Pharmacology and Therapeutics*, **2001**, 14, 315-9	3.5	28
21	Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. *Addiction*, **2000**, 95, 1771-83	4.6	40
20	Parkinson's disease and CYP1A2 activity. *British Journal of Clinical Pharmacology*, **2000**, 50, 303-9	3.8	14

19	The 1'-hydroxylation of Rac-bufuralol by rat brain microsomes. *Drug Metabolism and Disposition*, **2000**, 28, 1094-9	4	7
18	The antitussive effect of dextromethorphan in relation to CYP2D6 activity. *British Journal of Clinical Pharmacology*, **1999**, 48, 382-7	3.8	36
17	Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. *British Journal of Clinical Pharmacology*, **1999**, 48, 43-52	3.8	77
16	In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. *Pharmacogenetics and Genomics*, **1999**, 9, 277-86		44
15	Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. *Xenobiotica*, **1998**, 28, 1255-73	2	34
14	Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. *Pharmacogenetics and Genomics*, **1998**, 8, 227-38		92
13	Population-based modeling to demonstrate extrapancreatic effects of tolbutamide. *American Journal of Physiology - Endocrinology and Metabolism*, **1998**, 274, E758-71	6	6
12	The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 1458-61	5.6	34
11	Is Cmax/AUC useful for bioequivalence testing?. *Journal of Pharmaceutical Sciences*, **1997**, 86, 1504-5	3.9	7
10	The pharmacokinetics of methadone in healthy subjects and opiate users. *British Journal of Clinical Pharmacology*, **1997**, 44, 325-34	3.8	68
9	The Use of Tolbutamide-Induced Hypoglycemia to Examine the Intraislet Role of Insulin in Mediating Glucagon Release in Normal Humans. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 1458-1461	5.6	29
8	Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. *Pharmacogenetics and Genomics*, **1996**, 6, 121-49		111
7	Similar physiological and symptomatic responses to sulphonylurea and insulin induced hypoglycaemia in normal subjects. *Diabetic Medicine*, **1996**, 13, 634-41	3.5	14
6	The accumulation of mercaptopurine metabolites in age fractionated red blood cells. *British Journal of Clinical Pharmacology*, **1995**, 40, 217-22	3.8	19
5	Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game". *Journal of Pharmaceutical Sciences*, **1994**, 83, 1554-7	3.9	38
4	Debrisoquine and metoprolol oxidation in Zambians: a population study. *Pharmacogenetics and Genomics*, **1993**, 3, 205-8		27
3	Building Virtual Human Populations: Assessing the Propagation of Genetic Variability in Drug Metabolism to Pharmacokinetics and Pharmacodynamics425-446		
2	Precision medicine technology reality not hype - The example of model-informed precision dosing. *F1000Research*,8, 1709	3.6	

List of Publications

1 IN SILICO MODELING OF METABOLITE KINETICS213-237